MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors

Defining the role of mTOR in cancer

Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833

Phosphorylation of ULK1 (hATG1) by AMP-Activated Protein Kinase Connects Energy Sensing to Mitophagy

Egan, D. F., Shackelford, D. B., Mihaylova, M. M., Gelino, S., Kohnz, R. A., Mair, W., Vasquez, D. S., Joshi, A., Gwinn, D. M., Taylor, R., et al. (2011) · Science · doi:10.1126/science.1196371 · Cited by 2,600

mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt

O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC

Turke, A. B., Zejnullahu, K., Wu, Y.-L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.022 · Cited by 1,059

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity

Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P. K., Baselga, J., & Rosen, N. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.10.031 · Cited by 967

Activation of Akt and eIF4E Survival Pathways by Rapamycin-Mediated Mammalian Target of Rapamycin Inhibition

Sun, S., Rosenberg, L. M., Wang, X., Zhou, Z., Yue, P., Fu, H., & Khuri, F. R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0917 · Cited by 800

Mechanism for Activation of the EGF Receptor Catalytic Domain by the Juxtamembrane Segment

Jura, N., Endres, N., Engel, K., Deindl, S., Das, R., Lamers, M. H., Wemmer, D. E., Zhang, X., & Kuriyan, J. (2009) · Cell · doi:10.1016/j.cell.2009.04.025 · Cited by 609

Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor

Yeh, T. C., Marsh, V., Bernat, B. A., Ballard, J., Colwell, H., Evans, R. J., Parry, J., Smith, D. J., Brandhuber, B. J., Gross, S. D., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1150 · Cited by 578

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

Serra, V., Scaltriti, M., Prudkin, L., Eichhorn, P. J. A., Ibrahim, Y. H., Chandarlapaty, S., Markman, B., Rodríguez, O., Guzmán, M., Rodriguez, S., et al. (2011) · Oncogene · doi:10.1038/onc.2010.626 · Cited by 541

EGFR/uPAR interaction as druggable target to overcome vemurafenib acquired resistance in melanoma cells

Laurenzana, A., Margheri, F., Biagioni, A., Chillà, A., Pimpinelli, N., Ruzzolini, J., Peppicelli, S., Andreucci, E., Calorini, L., Serratì, S., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2018.12.024 · Cited by 45

Molecular design of dual inhibitors of PI3K and potential molecular target of cancer for its treatment: A review

Wang, Y., & Tortorella, M. D. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114039 · Cited by 44

Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer

Kennedy, S. P., Han, J. Z. R., Portman, N., Nobis, M., Hastings, J. F., Murphy, K. J., Latham, S. L., Cadell, A. L., Miladinovic, D., Marriott, G. R., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1127-y · Cited by 41

Cell type-dependent Erk-Akt pathway crosstalk regulates the proliferation of fetal neural progenitor cells

Rhim, J. H., Luo, X., Gao, D., Xu, X., Zhou, T., Li, F., Wang, P., Wong, S. T. C., & Xia, X. (2016) · Scientific Reports · doi:10.1038/srep26547 · Cited by 42

The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib

Park, K., Oh, B., Lee, M.-H., Nam, K., Jin, H. R., Yang, H., Choi, J., Kim, S., & Lee, D. H. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.12.015 · Cited by 41

A chemical screen in zebrafish embryonic cells establishes that Akt activation is required for neural crest development

Ciarlo, C., Kaufman, C. K., Kınıkoğlu, B., Jonathan, M., Yang, S. P., D'Amato, C. R., Blokzijl-Franke, S., den Hertog, J., Schlaeger, T. M., Zhou, Y., et al. (2017) · eLife · doi:10.7554/elife.29145 · Cited by 40

High-Throughput Functional Evaluation of MAP2K1 Variants in Cancer

Mizuno, S., Ikegami, M., Koyama, T., Sunami, K., Ogata, D., Kage, H., Yanagaki, M., Ikeuchi, H., Ueno, T., Tanikawa, M., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0302 · Cited by 45

Methylglyoxal Scavengers Resensitize KRAS-Mutated Colorectal Tumors to Cetuximab

Bellier, J., Nokin, M.-J., Caprasse, M., Tiamiou, A., Blomme, A., Scheijen, J. L., Koopmansch, B., MacKay, G. M., Chiavarina, B., Costanza, B., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.01.012 · Cited by 38

The Evolution of Our Molecular Understanding of Colorectal Cancer: What We Are Doing Now, What the Future Holds, and How Tumor Profiling Is Just the Beginning

Dienstmann, R., Salazar, R., & Tabernero, J. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.91 · Cited by 38

MAPK inhibitor sensitivity scores predict sensitivity driven by the immune infiltration in pediatric low-grade gliomas

Sigaud, R., Albert, T., Hess, C. C., Hielscher, T., Winkler, N., Kocher, D., Walter, C., Münter, D., Selt, F., Usta, D., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40235-8 · Cited by 41

Integrin-α7 signaling regulates connexin 43, M-cadherin, and myoblast fusion

McClure, M. J., Ramey, A. N., Rashid, M., Boyan, B. D., & Schwartz, Z. (2019) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00282.2018 · Cited by 39

Loss of FBXO31-mediated degradation of DUSP6 dysregulates ERK and PI3K-AKT signaling and promotes prostate tumorigenesis

Duan, S., Moro, L., Qu, R., Simoneschi, D., Cho, H., Jiang, S., Zhao, H., Chang, Q., de Stanchina, E., Arbini, A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109870 · Cited by 40

Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer

Kitai, H., Choi, P. H., Yang, Y. C., Boyer, J. A., Whaley, A., Pancholi, P., Thant, C., Reiter, J., Chen, K., Markov, V., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50063-z · Cited by 41

Interplay between cell cycle and autophagy induced by boswellic acid analog

Pathania, A. S., Guru, S. K., Kumar, S. G., Kumar, A., Ahmad, M. N., Bhushan, S., Sharma, P. R., Mahajan, P., Shah, B. A., Sharma, S., et al. (2016) · Scientific Reports · doi:10.1038/srep33146 · Cited by 38

A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours

Wilky, B. A., Rudek, M. A., Ahmed, S. R., Laheru, D. A., Cosgrove, D., Donehower, R. C., Nelkin, B. D., Ball, D. W., Doyle, L. A., Chen, H., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.515 · Cited by 37

IKBKE Is a Substrate of EGFR and a Therapeutic Target in Non–Small Cell Lung Cancer with Activating Mutations of EGFR

Challa, S., Guo, J.-P., Ding, X., Xu, C., Li, Y., Kim, D., Smith, M. A., Cress, W. D., Coppola, D., Haura, E. B., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0069 · Cited by 37

NF1 Is a Direct G Protein Effector Essential for Opioid Signaling to Ras in the Striatum

Xie, K., Colgan, L. A., Dao, M. T., Muntean, B. S., Sutton, L. P., Orlandi, C., Boye, S. L., Boye, S. L., Shih, C.-C., Li, Y., et al. (2016) · Current Biology · doi:10.1016/j.cub.2016.09.010 · Cited by 37

Activation of the EGFR / PI3K / AKT pathway limits the efficacy of trametinib treatment in head and neck cancer

Novoplansky, O., Shnerb, A. B., Marripati, D., Jagadeeshan, S., Shareb, R. A., Conde‐López, C., Zorea, J., Prasad, M., Lulu, T. B., Yegodayev, K. M., et al. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13500 · Cited by 37

Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status

Gaur, S., Chen, L., Ann, V., Lin, W., Wang, Y., Chang, V. H. S., Hsu, N. Y., Shia, H.-S., & Yen, Y. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-21 · Cited by 36

A novel function of HER2/Neu in the activation of G2/M checkpoint in response to γ-irradiation

Yan, Y., Hein, A. L., Greer, P. M., Wang, Z., Kolb, R. H., Batra, S. K., & Cowan, K. H. (2014) · Oncogene · doi:10.1038/onc.2014.167 · Cited by 36

FGFR4 Profile as a Prognostic Marker in Squamous Cell Carcinoma of the Mouth and Oropharynx

Dutra, R. L., de Carvalho, M. B., dos Santos, M. H., Mercante, A. M. D. C., Gazito, D., Cicco, R. D., GENCAPO Group, Tajara, E. H., Louro, I. D., & da Silva, A. M. Á. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050747 · Cited by 35

Sestrin 2 attenuates neonatal rat cardiomyocyte hypertrophy induced by phenylephrine via inhibiting ERK1/2

Dong, B., Xue, R., Sun, Y., Dong, Y., & Liu, C. (2017) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-017-3020-2 · Cited by 34

Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers

Hata, A. N., Rowley, S. C., Archibald, H. L., Gomez‐Caraballo, M., Siddiqui, F. M., Ji, F., Jung, J., Light, M. E., Lee, J. S., Debüssche, L., et al. (2017) · Oncogene · doi:10.1038/onc.2017.258 · Cited by 35

Pathway-Directed Therapy in Multiple Myeloma

John, L., Krauth, M. T., Podar, K., & Raab, M. (2021) · Cancers · doi:10.3390/cancers13071668 · Cited by 33

IL15 Agonists Overcome the Immunosuppressive Effects of MEK Inhibitors

Allegrezza, M. J., Rutkowski, M. R., Stephen, T. L., Svoronos, N., Tesone, A. J., Perales‐Puchalt, A., Nguyen, J. M., Sarmin, F., Sheen, M. R., Jeng, E. K., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2808 · Cited by 34

The limitations of targeting MEK signalling in Glioblastoma therapy

Selvasaravanan, K.-D., Burkert, N., Hadzalic, A., Strobel, H., Payer, C., Schuster, A., Karpel‐Massler, G., Siegelin, M. D., Halatsch, M., Debatin, K., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-64289-6 · Cited by 33

The Transcription Factor SLUG Uncouples Pancreatic Cancer Progression from the RAF–MEK1/2–ERK1/2 Pathway

Bilal, F., Arenas, E. J., Pedersen, K., Martínez-Sabadell, A., Nabet, B., Guruceaga, E., Vicent, S., Tabernero, J. M., Macarulla, T. M., & Arribas, J. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-4263 · Cited by 32

Obatoclax overcomes resistance to cell death in aggressive thyroid carcinomas by countering Bcl2a1 and Mcl1 overexpression

Champa, D., Russo, M. A., Liao, X. H., Refetoff, S., Ghossein, R. A., & Cristofano, A. D. (2014) · Endocrine Related Cancer · doi:10.1530/erc-14-0268 · Cited by 34

High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells

Horn, T. L., Ferretti, S., Ebel, N., Tam, A., Ho, S. B., Harbinski, F., Farsidjani, A., Zubrowski, M. J., Sellers, W. R., Schlegel, R., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3425 · Cited by 33

SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status

Daley, B. R., Vieira, H. M., Rao, C., Hughes, J. M., Beckley, Z., Huisman, D. H., Chatterjee, D., Sealover, N. E., Cox, K., Askew, J. W., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2313137120 · Cited by 30

Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer

Timsah, Z., Ahmed, Z., Ivan, C., Berrout, J., Gagea, M., Zhou, Y., Armaiz-Peña, G. N., Hu, X., Vallien, C., Kingsley, C. V., et al. (2015) · Oncogene · doi:10.1038/onc.2015.279 · Cited by 31

Preclinical evaluation of PI3K inhibitor BYL719 as a single agent and its synergism in combination with cisplatin or MEK inhibitor in nasopharyngeal carcinoma (NPC).

Wong, C. H., Ma, B. B. Y., Cheong, H. T., Hui, C. W. C., Hui, E. P., & Chan, A. T. �. (2015) · Europe PMC (PubMed Central) · Cited by 31

Integrin β1, myosin light chain kinase and myosin IIA are required for activation of PI3K-AKT signaling following MEK inhibition in metastatic triple negative breast cancer

Choi, C.-W., Kwon, J., Lim, S., & Helfman, D. M. (2016) · Oncotarget · doi:10.18632/oncotarget.11525 · Cited by 31

Combined targeting of Arf1 and Ras potentiates anticancer activity for prostate cancer therapeutics

Lang, L., Shay, C., Zhao, X., & Teng, Y. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0583-4 · Cited by 31

A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response

Xiao, Z., Carrasco, R. A., Schifferli, K. P., Kinneer, K., Tammali, R., Chen, H., Rothstein, R., Wetzel, L. K., Yang, C., Chowdhury, P. S., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0555 · Cited by 29

Blockage of the mevalonate pathway overcomes the apoptotic resistance to MEK inhibitors with suppressing the activation of Akt in cancer cells

Iizuka-Ohashi, M., Watanabe, M., Sukeno, M., Morita, M., Hoang, N. T. H., Kuchimaru, T., Kizaka‐Kondoh, S., Sowa, Y., Sakaguchi, K., Taguchi, T., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24696 · Cited by 29

Dual Targeting of Y-Box Binding Protein-1 and Akt Inhibits Proliferation and Enhances the Chemosensitivity of Colorectal Cancer Cells

Maier, E., Attenberger, F., Tiwari, A., Lettau, K., Rebholz, S., Fehrenbacher, B., Schaller, M., Gani, C., & Toulany, M. (2019) · Cancers · doi:10.3390/cancers11040562 · Cited by 29

All-Trans Retinoic Acid Induces Proliferation, Survival, and Migration in A549 Lung Cancer Cells by Activating the ERK Signaling Pathway through a Transcription-Independent Mechanism

Barceinas, R. S. Q., García-Regalado, A., Aréchaga-Ocampo, E., Villegas‐Sepúlveda, N., & la Rosa, C. H. G.-D. (2015) · BioMed Research International · doi:10.1155/2015/404368 · Cited by 28

A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS

Lieu, C. H., Hidalgo, M. M., Berlin, J. D., Ko, A. H., Cervantes, A. M. R., LoRusso, P. M., Gerber, D. E., Eder, J. P., Eckhardt, S. G., Kapp, A. V., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0175 · Cited by 28

Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer

Kitai, H., & Ebi, H. (2016) · Small GTPases · doi:10.1080/21541248.2016.1210369 · Cited by 28

Crosstalk between protein kinases AKT and ERK1/2 in human lung tumor-derived cell models

Stulpinas, A., Sereika, M., Vitkevičienė, A., Imbrasaitė, A., Krestnikova, N., & Kalvelytė, A. V. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1045521 · Cited by 28

Combining radiotherapy with MEK1/2, STAT5 or STAT6 inhibition reduces survival of head and neck cancer lines

Stegeman, H., Kaanders, J. H. A. M., Verheijen, M. M., Peeters, W. J. M., Wheeler, D. L., Iida, M., Grenman, R. A., van der Kogel, A. J., Span, P. N., & Bussink, J. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-133 · Cited by 27

Network rewiring, adaptive resistance and combating strategies in breast cancer

Cremers, C. G., & Nguyen, L. K. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.60 · Cited by 28

Effects of RAL signal transduction in KRAS- and BRAF-mutated cells and prognostic potential of the RAL signature in colorectal cancer

Győrffy, B., Stelniec‐Klotz, I., Sigler, C., Kasack, K., Redmer, T., Yu, Q., & Schäfer, R. (2015) · Oncotarget · doi:10.18632/oncotarget.3871 · Cited by 27

Ribosomal S6 kinase (RSK) modulators: a patent review

Ludwik, K. A., & Lannigan, D. A. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2016.1212839 · Cited by 26

Ataxin-1 is involved in tumorigenesis of cervical cancer cells via the EGFR-RAS–MAPK signaling pathway

Kang, A., An, H.-T., Ko, J., Choi, E., & Kang, S. (2017) · Oncotarget · doi:10.18632/oncotarget.21814 · Cited by 27

ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma

Capparelli, C., Purwin, T. J., Heilman, S. A., Chervoneva, I., McCue, P. A., Berger, A. C., Davies, M. A., Gershenwald, J. E., Krepler, C., & Aplin, A. E. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1001 · Cited by 27

Fluorescence resonance energy transfer based quantitative analysis of feedforward and feedback loops in epidermal growth factor receptor signaling and the sensitivity to molecular targeting drugs

Fujita, Y., Komatsu, N., Matsuda, M., & Aoki, K. (2014) · FEBS Journal · doi:10.1111/febs.12852 · Cited by 25

Unbiased in vivo preclinical evaluation of anticancer drugs identifies effective therapy for the treatment of pancreatic adenocarcinoma

Grbovic-Huezo, O., Pitter, K. L., Lecomte, N., Saglimbeni, J. A., Aşkan, G., Holm, M., Melchor, J. P., Chandwani, R., Joshi, S., Haglund, C. H., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1920240117 · Cited by 24

PSMG2-controlled proteasome-autophagy balance mediates the tolerance for MEK-targeted therapy in triple-negative breast cancer

Wang, X., Yu, J., Liu, X., Luo, D., Li, Y., Song, L., Jiang, X. L., Yin, X., Wang, Y., Chai, L., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100741 · Cited by 25

PIK3CA missense mutations promote glioblastoma pathogenesis, but do not enhance targeted PI3K inhibition

McNeill, R. S., Stroobant, E. E., Smithberger, E., Canoutas, D. A., Butler, M. K., Shelton, A., Patel, S. D., Limas, J. C., Skinner, K., Bash, R., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0200014 · Cited by 25

Oncogenic EML4-ALK assemblies suppress growth factor perception and modulate drug tolerance

Gonzalez-Martinez, D., Roth, L., Mumford, T. R., Guan, J., Le, A., Doebele, R. C., Huang, B., Tulpule, A., Niewiadomska–Bugaj, M., Bivona, T. G., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53451-7 · Cited by 24

Feedback analysis identifies a combination target for overcoming adaptive resistance to targeted cancer therapy

Park, S., Hwang, C. Y., Choi, J., Joung, C. Y., & Cho, K. (2020) · Oncogene · doi:10.1038/s41388-020-1255-y · Cited by 23

Therapeutic Landscape of Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Xie, J., Zou, Y., Gao, T., Xie, L., Tan, D., & Xie, X. (2022) · Cancer Control · doi:10.1177/10732748221099230 · Cited by 24

Novel therapeutics in low-grade serous ovarian cancer

Cobb, L. P., & Gershenson, D. M. (2023) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2022-003677 · Cited by 26

Climbing RAS, the Everest of Oncogenes

Russo, M., Nicolantonio, F. D., & Bardelli, A. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0906 · Cited by 25

Feedback activation of HER3 attenuates response to EGFR inhibitors in colon cancer cells

Bosch-Vilaró, A., Jacobs, B., Pomella, V., Asbagh, L. A., Kirkland, R. E., Michel, J., Singh, S., Liu, X., Kim, P., Weitsman, G. E., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13834 · Cited by 24

Krukovine Suppresses KRAS-Mutated Lung Cancer Cell Growth and Proliferation by Inhibiting the RAF-ERK Pathway and Inactivating AKT Pathway

Lai, H., Wang, Y., Duan, F., Li, Y., Jiang, Z., Luo, L., Liu, L., Leung, E. L., & Yao, X. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00958 · Cited by 24

Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors

Stewart, A., Thavasu, P., Bono, J. S. D., & Banerji, U. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv188 · Cited by 23

RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer

Koh, S., Ross, K. N., Isakoff, S. J., Melkonjan, N., He, L., Matissek, K. J., Schultz, A., Mayer, E. L., Traina, T. A., Carey, L., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0714 · Cited by 23

A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis

Galbán, S., Apfelbaum, A. A., Espinoza, C. E., Heist, K., Haley, H. R., Bedi, K., Ljungman, M. E., Galbán, C. J., Luker, G. D., Dort, M. V., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0207 · Cited by 22

Sorafenib and Carfilzomib Synergistically Inhibit the Proliferation, Survival, and Metastasis of Hepatocellular Carcinoma

Jiang, C., Xu, R., Li, X., Zhou, Y.-F., Xu, X.-Y., Yang, Y., Wang, H., & Zheng, X. F. S. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0541 · Cited by 23

A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance

Whitehead, C. E., Ziemke, E. K., Frankowski-McGregor, C. L., Mumby, R. A., Chung, J., Li, J., Osher, N., Coker, O., Baladandayuthapani, V., Kopetz, S., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00781-6 · Cited by 27

Inhibition of FGF receptor blocks adaptive resistance to RET inhibition in CCDC6-RET –rearranged thyroid cancer

Raman, R., Villefranc, J. A., Ullmann, T. M., Thiesmeyer, J. W., Anelli, V., Yao, J., Hurley, J. R., Pauli, C., Bareja, R., Eng, K., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20210390 · Cited by 22

Mechanisms of acquired resistance to HER2-Positive breast cancer therapies induced by HER3: A comprehensive review

Geng, W., Thomas, H., Chen, Z., Yan, Z., Zhang, P., Zhang, M., Huang, W., Ren, X., Wang, Z., Ding, K., et al. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176725 · Cited by 25

Cyclical Treatment of Colorectal Tumor Spheroids Induces Resistance to MEK Inhibitors

Thakuri, P. S., Luker, G. D., & Tavana, H. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.11.009 · Cited by 22

The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers

Saturno, G., Lopes, F., Niculescu-Duvaz, I., Niculescu-Duvaz, D., Zambon, A., Davies, L., Johnson, L., Preece, N., Lee, R., Viros, A., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.10.483 · Cited by 21

Blockade efficacy of MEK/ERK-dependent autophagy enhances PI3K/Akt inhibitor NVP-BKM120's therapeutic effectiveness in lung cancer cells

Ren, H. J., Guo, H., Thakur, A., Zhang, S., Wang, T., Liang, Y., Shi, P., Gao, L., Liu, F., Feng, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11645 · Cited by 21

HER2 and HER3 as Therapeutic Targets in Head and Neck Cancer

Saddawi‐Konefka, R., Schokrpur, S., Lui, A. J., & Gutkind, J. S. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000622 · Cited by 21

Clinical update on K-Ras targeted therapy in gastrointestinal cancers

Pant, S., Hubbard, J. M., Martinelli, E., & Bekaii‐Saab, T. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.07.011 · Cited by 21

Intracellular signaling control of mechanical homeostasis in the aorta

Irons, L., Estrada, A. C., & Humphrey, J. D. (2022) · Biomechanics and Modeling in Mechanobiology · doi:10.1007/s10237-022-01593-2 · Cited by 21

Anti‐angiogenic effects of the blue‐green alga Arthrospira platensis on pancreatic cancer

Markova, I., Koníčková, R., Vaňková, K., Leníček, M., Kolář, M., Strnad, H., Hradilová, M., Šáchová, J., Rasl, J., Klímová, Z., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14922 · Cited by 19

Role of Runx2 in Crosstalk Between Mek/Erk and PI3K/Akt Signaling in MCF‐10A Cells

Tandon, M., Chen, Z., & Pratap, J. (2014) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24939 · Cited by 20

High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition

Cai, J., Jacob, S., Kurupi, R., Dalton, K. M., Coon, C. M., Greninger, P., Egan, R. K., Stein, G. T., Murchie, E., McClanaghan, J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111095 · Cited by 19

Selumetinib: A Promising Pharmacologic Approach for KRAS -Mutant Advanced Non-Small-Cell Lung Cancer

Metro, G., Chiari, R., Baldi, A., Angelis, V. D., Minotti, V., & Crinò, L. (2013) · Future Oncology · doi:10.2217/fon.12.198 · Cited by 19

Preclinical Evaluation of Nintedanib, a Triple Angiokinase Inhibitor, in Soft-tissue Sarcoma: Potential Therapeutic Implication for Synovial Sarcoma

Patwardhan, P. P., Musi, E., & Schwartz, G. K. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0319 · Cited by 19

HMGA1 Modulates Gene Transcription Sustaining a Tumor Signalling Pathway Acting on the Epigenetic Status of Triple-Negative Breast Cancer Cells

Penzo, C., Arnoldo, L., Pegoraro, S., Petrosino, S., Ros, G., Zanin, R., Wiśniewski, J. R., Manfioletti, G., & Sgarra, R. (2019) · Cancers · doi:10.3390/cancers11081105 · Cited by 19

Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers

Son, J., Zhang, Y., Lin, H. Y., Mirallas, O., Ballesteros, P. Á., Nardo, M., Clark, N., Hillman, R. T., Campbell, E., Holla, V. R., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2819 · Cited by 19

Anthrax lethal factor cleaves regulatory subunits of phosphoinositide-3 kinase to contribute to toxin lethality

Mendenhall, M. A., Liu, S., Portley, M. K., O’Mard, D., Fattah, R. J., Szabo, R., Bugge, T. H., Khillan, J. S., Leppla, S. H., & Moayeri, M. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0782-1 · Cited by 18

Therapeutic Suppression of FAK-AKT Signaling Overcomes Resistance to SHP2 Inhibition in Colorectal Carcinoma

Li, Y., Yuan, Y., Zhang, F., Guo, A., Cao, F., Song, M., Fu, Y., Xu, X., Shen, H., Zheng, S., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.739501 · Cited by 17

Opposite and dynamic regulation of the interferon response in metastatic and non-metastatic breast cancer

Lamsal, A., Andersen, S. B., Johansson, I., Vietri, M., Bokil, A. A., Kurganovs, N. J., Rylander, F., Bjørkøy, G., Pettersen, K., & Giambelluca, M. S. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01062-y · Cited by 19

MEK inhibition drives anti-viral defence in RV but not RSV challenged human airway epithelial cells through AKT/p70S6K/4E-BP1 signalling

Baturcam, E., Vollmer, S., Schlüter, H., Maciewicz, R. A., Kurian, N., Vaarala, O., Ludwig, S., & Cunoosamy, D. M. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0378-7 · Cited by 18

Oncogenic K-Ras4B Dimerization Enhances Downstream Mitogen-activated Protein Kinase Signaling

Muratcioğlu, S., Aydın, C., Odabasi, E., Özdemir, E. S., Firat‐Karalar, E. N., Jang, H., Tsai, C., Nussinov, R., Kavaklı, İ. H., Gürsoy, A., et al. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.01.002 · Cited by 19

LC–MS/MS Bioanalytical Method for Quantification of Binimetinib and Venetoclax, and their Pharmacokinetic Interaction

Reddy, A., Jadav, T., Sahu, A. K., & Sengupta, P. (2021) · Bioanalysis · doi:10.4155/bio-2021-0207 · Cited by 18

Molecular Markers Predictive of Chemotherapy Response in Colorectal Cancer

Shiovitz, S., & Grady, W. M. (2015) · Current Gastroenterology Reports · doi:10.1007/s11894-015-0431-7 · Cited by 18

Eukaryotic Initiation Factor 4E (eIF4E) sequestration mediates 4E-BP1 response to rapamycin

Batool, A., Majeed, S. T., Aashaq, S., Majeed, R., Shah, G., Bhat, N. N., & Andrabi, K. I. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.12.102 · Cited by 18

Generation of a nanobody against HER2 tyrosine kinase using phage display library screening for HER2-positive breast cancer therapy development

Lamtha, T., Tabtimmai, L., Bangphoomi, K., Kiriwan, D., Malik, A. A., Chaicumpa, W., Henegouwen, P. M. P. V. B. E., & Choowongkomon, K. (2021) · Protein Engineering Design and Selection · doi:10.1093/protein/gzab030 · Cited by 17

Therapeutic Targeting of Cancer Stem Cells Prevents Resistance of Colorectal Cancer Cells to MEK Inhibition

Lamichhane, A., Thakuri, P. S., Singh, S. K., Nejad, P. R., Heiss, J., Luker, G. D., & Tavana, H. (2022) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00257 · Cited by 17

Advancements in dual-target inhibitors of PI3K for tumor therapy: Clinical progress, development strategies, prospects

Hu, J., Fu, S., Zhan, Z., & Zhang, J. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116109 · Cited by 19

Loss of EGFR confers acquired resistance to AZD9291 in an EGFR-mutant non-small cell lung cancer cell line with an epithelial–mesenchymal transition phenotype

Xu, J., Zhao, X., He, D., Wang, J., Li, W., Liu, Y., Ma, L., Jiang, M., Yu, T., Wang, Z., et al. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2668-7 · Cited by 16

Pancreatic ductal adenocarcinoma: Emerging therapeutic strategies

Osei‐Bordom, D., Serifis, N., Brown, Z. J., Hewitt, D. B., Lawal, G., Sachdeva, G. S., Cloonan, D. J., & Pawlik, T. M. (2022) · Surgical Oncology · doi:10.1016/j.suronc.2022.101803 · Cited by 17

SOS2 modulates the threshold of EGFR signaling to regulate osimertinib efficacy and resistance in lung adenocarcinoma

Theard, P. L., Linke, A. J., Sealover, N. E., Daley, B. R., Yang, J. J., Cox, K., & Kortum, R. L. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13564 · Cited by 17

Past and Future Strategies to Inhibit Membrane Localization of the KRAS Oncogene

Haidar, M., & Jacquemin, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413193 · Cited by 18

p27kip1 expression and phosphorylation dictate Palbociclib sensitivity in KRAS-mutated colorectal cancer

Vinciguerra, G. L. R., Dall’Acqua, A., Segatto, I., Mattevi, M. C., Russo, F., Favero, A., Cirombella, R., Mungo, G., Viotto, D., Karimbayli, J., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04241-2 · Cited by 16

Fine-tuning of MEK signaling is pivotal for limiting B and T cell activation

Houde, N., Beuret, L., Bonaud, A., Fortier-Beaulieu, S.-P., Truchon-Landry, K., Aoidi, R., Pic, É., Alouche, N., Rondeau, V., Schlecht‐Louf, G., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2021.110223 · Cited by 16

Structural analysis of cannabinoids against EGFR-TK leads a novel target against EGFR-driven cell lines

Lamtha, T., Tabtimmai, L., Songtawee, N., Tansakul, N., & Choowongkomon, K. (2022) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2022.100132 · Cited by 15

WNT5A augments cell invasiveness by inducing CXCL8 in HER2-positive breast cancer cells

Kim, S., You, D., Jeong, Y., Yoon, S. Y., Kim, S. A., Kim, S. W., Nam, S. J., & Lee, J. E. (2020) · Cytokine · doi:10.1016/j.cyto.2020.155213 · Cited by 15

The overview of Mitogen-activated extracellular signal-regulated kinase (MEK)-based dual inhibitor in the treatment of cancers

Wang, H., Chi, L., Yu, F., Dai, H., Si, X., Gao, C., Wang, Z., Liu, L., Zheng, J., Ke, Y., et al. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.116922 · Cited by 15

Bcl-xl and Mcl-1 are the major determinants of the apoptotic response to dual PI3K and MEK blockage

Jokinen, E., & Koivunen, J. P. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3071 · Cited by 16

A Probabilistic Boolean Network Approach for the Analysis of Cancer-Specific Signalling: A Case Study of Deregulated PDGF Signalling in GIST

Trairatphisan, P., Wiesinger, M., Bahlawane, C., Haan, S., & Sauter, T. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156223 · Cited by 15

Abstract 5632: MEK inhibition leads to elevated HER3:PI3K in EGFR or HER2 driven cancer through feedback induction of HER1:3 and HER2:3 dimers.

Hoe, N., Mateling, M., Ma, Y., Jin, K., Zhou, J., Kirkland, R. E., Kuy, C., Liu, X., Kim, P., & Singh, S. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-5632

MEK inhibitors induce Akt activation and drug resistance by suppressing negative feedback ERK ‐mediated HER 2 phosphorylation at Thr701

Chen, C., Hsia, T., Yeh, M., Chen, T.-H., Chen, Y., Chen, J., Wei, Y., Tu, C., & Huang, W. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12102 · Cited by 65

Abstract 2321: Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS signaling.

Will, M., Toy, W., Yao, Z., Poulikakos, P. I., Rodrik-Outmezguine, V. S., Schneider, C., Paul, J., Baselga, J. M., Liu, N., Rosen, N. X., et al. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-2321

The crossregulation between ERK and PI3K signaling pathways determines the tumoricidal efficacy of MEK inhibitor

Won, J., Yang, H. W., Shin, S., Lee, J., Heo, W. D., & Cho, K. (2012) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjs021 · Cited by 75

Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells

Yuen, H., Abramczyk, O., Montgomery, G. W., Chan, K.-K., Huang, Y., Sasazuki, T., Shirasawa, S., Gopesh, S., Chan, K.-W., Fennell, D. A., et al. (2012) · Bioscience Reports · doi:10.1042/bsr20120050 · Cited by 33